Costs and Benefits of Implementing Non-Invasive Prenatal Testing For Trisomy 21 (T21) Based on Cell Free DNA (CFDNA) Sequencing In Maternal Plasma In France
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1938
https://www.valueinhealthjournal.com/article/S1098-3015(17)32272-6/fulltext
Title :
Costs and Benefits of Implementing Non-Invasive Prenatal Testing For Trisomy 21 (T21) Based on Cell Free DNA (CFDNA) Sequencing In Maternal Plasma In France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32272-6&doi=10.1016/j.jval.2017.08.1938
First page :
A721
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1760